Full-Time
Manager – Field & Marketing Operations
Speaker Bureau
Posted on 8/3/2026
Rhythm Pharmaceuticals
201-500 employees
Commercializes MC4R-targeted therapies for rare obesity
Compensation Overview
$110k - $165k/yr
Boston, MA, USA
Hybrid
Hybrid work with required Boston office attendance coordinated with department and business needs; up to 30% travel.
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree or a combination of education and relevant work experience.
- At least 5 years of experience in administration and management of commercial operations logistics across meetings, speaker bureaus, and/or congresses within a pharmaceutical company or primary pharmaceutical service provider; rare disease experience is a plus.
- At least 2 years of project management or coordinator experience within the peer-to-peer, medical education, and/or speaker bureau industry for life sciences.
- At least 2 years of experience as a speaker bureau coordinator or meeting planner within the pharmaceutical industry.
- Experience managing vendor partners or consultants and leading project teams to achieve milestones and objectives.
- Strong understanding of PhRMA Guidelines and the Sunshine Act.
- Proficiency with Microsoft Office applications, including Outlook, PowerPoint, Word, Excel, and Teams, as well as Salesforce and Veeva PromoMats.
- Proficiency in using technology to optimize business operations and support cross-functional initiatives, including learning and leveraging digital tools and platforms for strategic decision-making and team productivity.
- Ability to meet business objectives and deliverables and complete initiatives on time with cross-functional teams.
- Effective planning, organizational, and prioritization skills to achieve established deadlines.
- Demonstrated program ownership and consistent delivery on commitments.
- Strong interpersonal skills and ability to collaborate with external experts, cross-functional partners, and field-based teams.
- Ability to work independently.
- Willingness and ability to work in the Boston office under the hybrid-work model.
- Willingness to travel up to 30%.
- Manage all aspects of speaker bureau coordination, including venue selection, travel, materials, technology, and execution, serving as the primary contact for speakers, field teams, internal departments, vendors, and attendees.
- Organize and manage speaking engagements, speaker bureau programs, and related training in compliance with company policies, standard procedures, and business rules.
- Implement metrics plans and optimization and manage quarterly business reviews of programs.
- Ensure speaker programs adhere to regulatory guidelines, including FDA, PhRMA, and Sunshine Act requirements.
- Manage documentation, expense tracking, and reporting for transparency and audit readiness.
- Collaborate with Legal and Compliance teams to update policies and procedures.
- Create marketing materials for field teams and headquarters to promote programs.
- Supervise and handle financial disbursements to speakers and vendors for programs.
- Partner with Medical Affairs, Marketing, Sales, and Events teams to align speaker bureau activities with strategic goals.
- Serve as the point of contact for speaker-related inquiries and issue resolution.
- Provide regular updates and performance metrics to leadership.
- Serve as the key logistical contact for healthcare professional, key opinion leader, and advisory activities at conferences.
- Create marketing materials for field teams and headquarters to promote conference activities where allowed.
- Lead product theaters at key congresses, including materials, invitations, and speaker management.
- Optimize organizational presence and key customer engagements through coordination with Brand, Sales, Medical, and other internal partners.
- Serve as the onsite liaison between Rhythm and conference associations and attend Rhythm events requiring support.
- Collaborate on and contribute to special projects as needed.
- Work cross-functionally with the marketing team on Advisory Board logistics, North America Meeting Planning, POA Meetings, and related initiatives.
- Rare disease experience.
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2008
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 IMCIVREE revenue reached $71.3 million, up 19% sequentially.
- August 2026 RM-718 delivered 11.6% BMI reduction at week 16 in HO patients.
- August 2026 Manher Joshi joined as CMO, strengthening late-stage development execution.
What critics are saying
- March 2026 EMANATE missed four primary endpoints, weakening expansion beyond current labels.
- IMCIVREE depends on rare-disease diagnosis, payer access, and narrow prescriber adoption.
- Setmelanotide-class adverse events, including nausea and injection reactions, threaten chronic-use persistence.
What makes Rhythm Pharmaceuticals unique
- March 2026 FDA approved IMCIVREE first for acquired hypothalamic obesity.
- Rhythm owns MC4R biology, spanning setmelanotide, bivamelagon, and RM-718 programs.
- BBS and genetic-obesity diagnostics create a rare, specialist-driven commercial moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 3%Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.
Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.
Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE, marking a 19% sequential increase from the first quarter. The company received over 400 patient start forms for IMCIVREE's acquired hypothalamic obesity indication from approximately 300 prescribers as of 30 June 2026, following FDA approval in March. US revenue reached $51.0 million, representing 72% of product revenue and a 38% sequential increase, driven primarily by acquired hypothalamic obesity demand. The company reported preliminary Phase 2 data showing weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in acquired hypothalamic obesity patients after 16 weeks. Cash, cash equivalents, and short-term investments totalled approximately $330.9 million as of 30 June 2026. The company posted a net loss of $50.4 million for the quarter.
Rhythm Pharmaceuticals has published an updated diagnostic algorithm for Bardet-Biedl syndrome in the American Journal of Medical Genetics, designed to help clinicians achieve faster diagnoses using modern genetic testing. The evidence-based framework simplifies recognition of the complex, multi-organ rare disease across age groups and specialties. The new algorithm could expand identification of eligible patients for Rhythm's IMCIVREE treatment and strengthen relationships with the Bardet-Biedl syndrome community and physicians. This follows Rhythm's recent expanded indication for IMCIVREE in acquired hypothalamic obesity in the US and Europe. Whilst the algorithm may broaden patient identification, investors remain focused on Rhythm's commercial execution, persistent operating losses and reliance on setmelanotide. The company's investment case depends on converting rare genetic obesity awareness into sustainable treatment demand.